GGrantIndex
← Search

Developmental Therapeutics Core Facility

$125,721P30FY2014CANIH

Northwestern University At Chicago, Evanston IL

Investigators

Linked publications, trials & patents

Trial NCT07639528Trial NCT07594626Trial NCT07594548Trial NCT07290543Trial NCT07261657Trial NCT07178301Trial NCT07169617Trial NCT07050186Trial NCT07042919Trial NCT06959641Trial NCT06813898Trial NCT06723457Trial NCT06630416Trial NCT06571734Trial NCT06499870Trial NCT06410248Trial NCT06327477Trial NCT06247540Trial NCT06244004Trial NCT06242834Trial NCT06184750Trial NCT06164275Trial NCT06137651Trial NCT06062498Trial NCT06060587Trial NCT06022822Trial NCT05879250Trial NCT05852041Trial NCT05802186Trial NCT05744739Trial NCT05733000Trial NCT05620771Trial NCT05576896Trial NCT05545150Trial NCT05453799Trial NCT05419011Trial NCT05411107Trial NCT05236036Trial NCT05202782Trial NCT05093387Trial NCT04931017Trial NCT04910425Trial NCT04795869Trial NCT04767984Trial NCT04753216Trial NCT04576104Trial NCT04550481Trial NCT04250051Trial NCT04227028Trial NCT04200443Trial NCT04049227Trial NCT04047706Trial NCT04033432Trial NCT04009044Trial NCT03854474Trial NCT03812562Trial NCT03742258Trial NCT03723915Trial NCT03704714Trial NCT03513484Trial NCT03317405Trial NCT03278925Trial NCT03226249Trial NCT03213041Trial NCT03146650Trial NCT03077828Trial NCT03070002Trial NCT03061188Trial NCT03048500Trial NCT03044730Trial NCT03036930Trial NCT03020017Trial NCT02993159Trial NCT02968810Trial NCT02965703Trial NCT02901899Trial NCT02892734Trial NCT02871323Trial NCT02861040Trial NCT02847559Trial NCT02837029Trial NCT02819804Trial NCT02808143Trial NCT02805868Trial NCT02794883Trial NCT02774681Trial NCT02743364Trial NCT02720484Trial NCT02694809Trial NCT02536794Trial NCT02530619Trial NCT02530502Trial NCT02530125Trial NCT02481310Trial NCT02365480Trial NCT02357810Trial NCT02314156Trial NCT02242097Trial NCT02237183Trial NCT02232516

Abstract

PROJECT SUMMARY (See instructions): The Developmental Therapeutics Core (DTC) works with RHLCCC investigators to facilitate translation of new oncology therapeutic agents to the clinic. DTC provides a range of services that include in vitro tumor cell line assays such as the NCI60 panel, proliferation, apoptosis, cytotoxicity, migration and invasion assays. Animal studies run by DTC include a variety of subcutaneous and orthotopic models of tumor growth and metastasis that can be used to study mechanism and evaluate new drug candidates, exploratory pharmacokinetics (in collaboration with the RHLCCC funded Clinical Pharmacology Core), and exploratory toxicology including histopathological evaluation. In addition, DTC assist investigators with drug formulation and initial assessments of drug stability. DTC staff are proficient using all routes of administration including PO by gavage, IV, IP, and SC and in small animal surgery, which allows for implantation of osmotic minipumps for continuous infusion. To date, DTC has collaborated with a broad spectrum of different investigators including clinicians looking to evaluate new drugs or combinations before moving these into the clinic and basic science researchers such as chemists or individuals who lack tumor biology or animal model expertise. DTC has also collaborated with the Center for Molecular Innovation and Drug Discovery (CMIDD) to carry out initial in vitro evaluation for a number of early discovery projects. DTC also advises on study design and provides consulting and training to faculty and students. DTC has been able to accelerate implementation of studies by working with the lACUC to set up and manage a number of blanket proposals under which it can run most of these studies that it engages in simply by filing a one page study-specific addendum describing the cell line used, if applicable, and the drug to be studied. DTG routinely adds fellows and students to these protocols in order to facilitate hands-on training. DTC currently has one full time and one part time FTE in addition to the director but is in the process of hiring two additional research associates to meet the growing demand for its services. DTC currently occupies bench and office space in Silverman Hall West it carries out all of its animal work in the vivarium that is located in Pancoe Hall, which adjoins Silverman Hall. In addition, DTC carries out a number of studies in collaboration with the Molecular and Translational Imaging Core (MTIC). DTC routinely labels most of its cell lines using Luc2 and dTomato (bioluminescence and fluorescence, respectively), which allows real time monitoring of orthotopic tumor growth and metastasis using the IMTIC facilities for this purpose. Finally, in addition to increasing staff to meet the demand for existing models, DTC is collaborating with the pathology core facility (PCF) to develop a novel repository of patient-derived xenografts across a variety of histologies that will only be passaged in vivo.

View original record on NIH RePORTER →